单位：[1]Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11 Xizhimen Nandajie, Beijing 100044, China.[2]Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.[3]Department of Endocrinology, Peking University First Hospital, Beijing, China.[4]Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.[5]Department of Endocrinology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.中山大学附属第三医院[6]Department of Endocrinology, Shanghai Sixth People’s Hospital, Shanghai, China.[7]Department of Endocrinology, Changhai Hospital, Second Military Medical University, Shanghai, China.[8]Department of Endocrinology, Second Xiangya Hospital of Central South University, Changsha, China.[9]Department of Endocrinology, Tianjin Medical University Metabolic Disease Hospital, Tianjin, China.[10]Department of Endocrinology, Shanxi Provincial People’s Hospital, Taiyuan, China.[11]Department of Endocrinology, First Hospital of China Medical University, Shenyang, China.[12]Department of Endocrinology, Heilongjiang Province Hospital, Harbin, China.[13]Department of Endocrinology, Huashan Hospital, Fudan University, Shanghai, China.[14]Department of Endocrinology, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China.[15]Department of Endocrinology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.[16]Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, China.[17]Department of Endocrinology, Henan Provincial People’s Hospital, Zhengzhou, China.[18]Department of Endocrinology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.重庆医科大学附属第一医院[19]Department of Endocrinology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[20]Department of Endocrinology, Xijing Hospital, Fourth Military Medical University, Xi’an, China.[21]Department of Endocrinology, Gansu Provincial Hospital, Lanzhou, China.[22]Department of Endocrinology, Xinjiang Uigur Autonomous Region People’s Hospital, Urumqi, China.[23]Department of Endocrinology, Affiliated Hospital of Guiyang Medical College, Guiyang, China.[24]Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Background: The prevalence of type 2 diabetes mellitus (T2DM) is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs (OADs), glucagon-like peptide-1 (GLP-1) receptor agonists, and insulin for treatment of T2DM across multiple regions in China. Methods: This was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011. Results: A total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone (n=157,212 [65.88%]), OADs plus insulin (n=80,973 [33.93%]), or OADs plus GLP-1 receptor agonists (n=454 [0.19%]). The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin (HbA1c) levels (+/- SD) of 7.67% (+/- 1.58%), 8.21% (+/- 1.91%), and 7.80% (+/- 1.76%), respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM. Conclusions: Less than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.
基金：
Novo Nordisk (China) Pharmaceutical Co., Ltd (NNCP)Novo Nordisk
第一作者单位：[1]Department of Endocrinology and Metabolism, Peking University People’s Hospital, No. 11 Xizhimen Nandajie, Beijing 100044, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Li-Nong Ji,Ju-Ming Lu,Xiao-Hui Guo,et al.Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables[J].BMC PUBLIC HEALTH.2013,13:doi:10.1186/1471-2458-13-602.
APA：
Li-Nong Ji,Ju-Ming Lu,Xiao-Hui Guo,Wen-Ying Yang,Jian-Ping Weng...&Yan-Cheng Xu.(2013).Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables.BMC PUBLIC HEALTH,13,
MLA：
Li-Nong Ji,et al."Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables".BMC PUBLIC HEALTH 13.(2013)
